Stock Events

Stock Events

Pharmamar.

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

23AprExpected

Q4 2025

Next

0.12

1.19

2.25

3.31

Expected EPS

0.123162442

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PMRA.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Merck & Co., Inc. is a global healthcare company that develops medications in areas similar to Pharmamar, including oncology, making it a direct competitor in the cancer treatment market.

Bristol-Myers Squibb

Bristol-Myers Squibb operates in the biopharmaceutical industry focusing on cancer, a key area for Pharmamar, making them competitors in developing and commercializing oncology treatments.

Pfizer Inc. is a large pharmaceutical company with a broad product line that includes oncology treatments, competing with Pharmamar in the cancer drug market.

AstraZeneca PLC focuses on the discovery, development, and commercialization of prescription medicines, including those for cancer, directly competing with Pharmamar in the oncology sector.

Gilead Sciences

Gilead Sciences, Inc. is known for its innovative therapies in areas like oncology, directly competing with Pharmamar in the development of cancer treatments.

Novartis AG operates globally in the pharmaceutical sector, with a strong emphasis on oncology, making it a competitor to Pharmamar in the cancer treatment market.

Roche Holding AG focuses on pharmaceuticals and diagnostics with a strong portfolio in oncology, competing with Pharmamar in cancer treatment innovations.

Amgen Inc. is a biotechnology company focusing on human therapeutics, including oncology, which puts it in direct competition with Pharmamar in the biopharmaceutical sector.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is involved in the discovery, development, and commercialization of medicines for serious medical conditions, including cancer, making it a competitor to Pharmamar.

Johnson & Johnson

Johnson & Johnson operates in the pharmaceutical and healthcare sectors, with a focus on developing treatments for various diseases, including cancer, positioning it as a competitor to Pharmamar in the healthcare market.

About

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Show more...

CEO

Mr. Jose Maria Fernandez Sousa-Faro

Employees

477

Country

Spain

ISIN

ES0169501022

Listings

0 Comments

Share your thoughts

FAQ

What is Pharmamar. stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Pharmamar. stocks are traded under the ticker PMRA.MU.

When is the next Pharmamar. earnings date?▼

Pharmamar. is going to release the next earnings report on April 23, 2026.

What were Pharmamar. earnings last quarter?▼

PMRA.MU earnings for the last quarter are 3.31 EUR per share, whereas the estimation was 3.05 EUR resulting in a +8.63% surprise. The estimated earnings for the next quarter are N/A EUR per share.

How many employees does Pharmamar. have?▼

As of April 12, 2026, the company has 477 employees.

In which sector is Pharmamar. located?▼

Pharmamar. operates in the Health & Wellness sector.

When did Pharmamar. complete a stock split?▼

Pharmamar. has not had any recent stock splits.

Where is Pharmamar. headquartered?▼

Pharmamar. is headquartered in Madrid, Spain.